New and Special Drug
Atled (Fanregratinib) – Intrahepatic Cholangiocarcinoma | HongKong DengYue Medicine
Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine
Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
Exdensur (Depemokimab) – Eosinophilic Asthma | HongKong DengYue Medicine
Adempas (Riociguat) – CTEPH/PAH | HongKong DengYue Medicine
Biktarvy (Bictegravir/Emtricitabine/TAF) – HIV-1 | HongKong DengYue Medicine
Simulect (Basiliximab) – Renal Transplantation | HongKong DengYue Medicine
Enboke (Anti-Human Interleukin) – Inflammatory Skin Diseases | HongKong DengYue Medicine
Poteligeo (Mogamulizumab) – CTCL | HongKong DengYue Medicine
Rabineutra (Ormutivimab) – Rabies PEP | HongKong DengYue Medicine
Brii Biosciences (Amubarvimab) – COVID-19 | HongKong DengYue Medicine
SINTBILO (Tafolecimab) – Hypercholesterolemia | HongKong DengYue Medicine
Hansizhuang (Serplulimab) – Solid Tumors | HongKong DengYue Medicine
Ovidrel (rhCG) – Ovulation Induction | HongKong DengYue Medicine
CIMAher (Nimotuzumab) – HNSCC | HongKong DengYue Medicine
